AI assistant
Sending…
VYNE Therapeutics Inc. — Director's Dealing 2021
Jan 5, 2021
35290_dirs_2021-01-05_263e2dd0-bafe-4884-94d5-146e951a5b6a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VYNE Therapeutics Inc. (VYNE)
CIK: 0001566044
Period of Report: 2020-12-31
Reporting Person: Domzalski David (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Common Stock | F | 9656 | $1.58 | Disposed | 1304334 | Direct |
Footnotes
F1: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.